View of Preclinical Study of 177Lu-DOTA-Trastuzumab: A Potential Radiopharmaceutical for Therapy of Breast Cancer Positive HER-2

Return to Article Details Preclinical Study of 177Lu-DOTA-Trastuzumab: A Potential Radiopharmaceutical for Therapy of Breast Cancer Positive HER-2 Download Download PDF